Presentation is loading. Please wait.

Presentation is loading. Please wait.

Phase II Randomized Study of Two Regimens of Sequentially Administered Mitomycin C and Irinotecan in Patients with Unresectable Esophageal and Gastroesophageal.

Published byElmar Walter Modified over 5 years ago

Similar presentations

Presentation on theme: "Phase II Randomized Study of Two Regimens of Sequentially Administered Mitomycin C and Irinotecan in Patients with Unresectable Esophageal and Gastroesophageal."— Presentation transcript:

1 Phase II Randomized Study of Two Regimens of Sequentially Administered Mitomycin C and Irinotecan in Patients with Unresectable Esophageal and Gastroesophageal Adenocarcinoma  Maryam B. Lustberg, MD, Tanios Bekaii-Saab, MD, Donn Young, PhD, Gregory Otterson, MD, William Burak, MD, Abbas Abbas, MD, Barbara McCracken-Bussa, BA, Mark E. Lustberg, MD, PhD, Miguel A. Villalona-Calero, MD  Journal of Thoracic Oncology  Volume 5, Issue 5, Pages (May 2010) DOI: /JTO.0b013e3181d7776d Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 A, Plot of percentage change in computed tomography (CT) tumor size by arm. Individual percentage change in tumor size by CT scan according to the treatment arm (n = 30). B, Plot of percentage change in standard uptake values (SUV) by arm. Individual percentage change in tumor SUV by positron emission tomography according to the treatment arm (n = 38). Two additional patients with progressive disease because of new metabolic lesions were not included. Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181d7776d) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 A, Kaplan-Meier plots of progression free survival by percentage change in standard uptake values (SUV). Kaplan-Meier plots showing progression-free survival according to percent decreases in SUV >25% and <25%. There is a statistically significant difference between patients with and without a metabolic response (P = 0.02). B, Kaplan-Meier plots of overall survival by percentage change in SUV. Kaplan-Meier plots showing overall survival according to percent decreases in SUV >25% and <25%. There is a statistically significant difference between patients with and without a metabolic response (P = 0.006). Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181d7776d) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Phase II Randomized Study of Two Regimens of Sequentially Administered Mitomycin C and Irinotecan in Patients with Unresectable Esophageal and Gastroesophageal."

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R

Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R
Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.
Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.
CALGB 30704 (Alliance): A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib or Pemetrexed Plus Sunitinib in the Second-Line.

CALGB (Alliance): A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib or Pemetrexed Plus Sunitinib in the Second-Line.
Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 

Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 
Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.
Utility of 18F-FDG PET for Predicting Histopathologic Response in Esophageal Carcinoma following Chemoradiation  Andrea L.H. Arnett, MD, PhD, Kenneth.

Utility of 18F-FDG PET for Predicting Histopathologic Response in Esophageal Carcinoma following Chemoradiation  Andrea L.H. Arnett, MD, PhD, Kenneth.
Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.
Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Jos A. Stigt, MD, PhD, Richard Vossenkaul, MD, Wouter H

Jos A. Stigt, MD, PhD, Richard Vossenkaul, MD, Wouter H
Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer

Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer
First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status  Young Joo Lee, MD, Heung Tae Kim, MD,

First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status  Young Joo Lee, MD, Heung Tae Kim, MD,
Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer  Hiroyasu Kaneda, MD, PhD, Isamu.

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer  Hiroyasu Kaneda, MD, PhD, Isamu.
Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD-1/PD-L1.

Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD-1/PD-L1.
Role of CT and PET Imaging in Predicting Tumor Recurrence and Survival in Patients with Lung Adenocarcinoma  Ho Yun Lee, MD, PhD, So Won Lee, MD, Kyung.

Role of CT and PET Imaging in Predicting Tumor Recurrence and Survival in Patients with Lung Adenocarcinoma  Ho Yun Lee, MD, PhD, So Won Lee, MD, Kyung.
Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 

Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 
Surgical treatment of metachronous second primary lung cancer after complete resection of non–small cell lung cancer  Masatsugu Hamaji, MD, Mark S. Allen,

Surgical treatment of metachronous second primary lung cancer after complete resection of non–small cell lung cancer  Masatsugu Hamaji, MD, Mark S. Allen,
Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Similar presentations

Ads by Google